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Aim: To assess the role of doctors who patients report as responsible of their
disease, in moderate–severe chronic obstructive pulmonary disease (COPD),
describing characteristics of patients and treatments use according to each type
of doctor, and relating it to the way of access to hospital at the time of an
exacerbation.
Materials/patients and methods: A systematic sample of 1:2 patients admitted for
a COPD exacerbation during 1 year in four tertiary hospitals in the Barcelona area,
Spain, was recruited. Information about health services was obtained by an
administered questionnaire.Elsevier Ltd. All rights reserved.
2211009; fax: +34 93 2216448.
. Garcia-Aymerich).
d’Aguditzacio´ de la MPOC (Risk Factors of COPD Exacerbation Study). The EFRAM investigators
tor), Judith Garcia-Aymerich and Jordi Sunyer from the Respiratory and Environmental Health
Alonso from the Health Services Research Unit, IMIM, Barcelona; Esther Barreiro and Miquel A.
logy, Hospital del Mar, Barcelona; Joan Escarrabill, Eva Farrero and M
%
a Jose´ Redondo from the
niversitari de Bellvitge, L’Hospitalet de Llobregat; Ramon M. Marrades, Ne´stor Soler and Antoni
logy, Hospital Clı´nic i Provincial de Barcelona, Barcelona; Glo`ria Bonet, Jose´ Izquierdo, Eduard
artment of Pneumology, Hospital Germans Trias i Pujol, Badalona.
ARTICLE IN PRESS
Health care in COPD Patients 333Results: A total of 346 patients were recruited: mean age 69 (79) years, percent of
predicted FEV1 of 35 (716)%, PO2 of 64 (713)mmHg. At the time of admission, 17%
of patients reported being controlled by a general practitioner (GP) and 56% by a
pneumologist whereas 21% reported its COPD not being under the regular control of
any doctor. Patients not controlled by a pneumologist did not suffer from milder
COPD than the remaining, but were less likely to receive pharmacological and non-
pharmacological treatments and less likely to perform correctly the inhalation
manoeuvres. During the course of the exacerbation 70% of patients reported a visit
to a hospital emergency room department without a previous medical visit, this
proportion being higher among those controlled by a pneumologist.
Conclusions: Lack of control and variability in the patterns of care among patients
controlled by different types of physicians are common in moderate-to-severe COPD
patients admitted for a COPD exacerbation, despite the lack of differences in COPD
severity. Medical control of COPD patients needs more investigation and a wider
inclusion in international guidelines.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Acute exacerbations during the course of the
chronic obstructive pulmonary disease (COPD) are
one of the most important causes of hospital
admission in western countries, mainly during the
winter period.1,2 Exacerbations and, specially,
admissions due to exacerbation, have a large
impact on quality of life,3 increase the mortality,4
and involve a large economic cost. Exacerbations of
COPD are considered to be responsible of more than
35% of the global cost of COPD care.5 Furthermore,
increased winter emergency admissions disrupt
elective admissions directly affecting waiting lists,6
saturating emergency rooms (ERs) and not uncom-
monly inducing episodes of social concern with high
echoing in the media. The importance of the
economic and clinical consequences of COPD has
fostered the research on new modalities of clinical
management of COPD exacerbation, chiefly home
delivered.7 However, most COPD guidelines do not
provide recommendations for the appropriate
provision of current health services to patients.
Although the 1995 ATS statement provided an
indication of when a COPD patient should be
controlled for a respiratory specialist,8 to our
knowledge, no research has been done to assess
differential characteristics and effects of control
by each type of physician in COPD patients. Two
manuscripts, written in Dutch, were partly devoted
to this issue in asthma and chronic bronchitis
patients,9,10 but their results can not be extra-
polated to COPD.
In the EFRAM study we carried out an extended
search of risk factors of hospital admission by a
COPD exacerbation and included a wide assessment
of how moderate and severe COPD patients were
being controlled for their disease.11,12 In thepresent manuscript we focus on the role of doctors
who patients reported as responsible of their COPD,
describing characteristics of patients and treat-
ments use according to each type of doctor, and
relating it to the way of access to hospital at the
time of an exacerbation.Methods
Design and subjects
Descriptive study of a cross-sectional systematic
sample of 1 out of every 2 patients hospitalised or
remaining in the ER for at least 18 h for a COPD
exacerbation in four tertiary hospitals in the
Barcelona area over the recruitment year (from
May 1, 1997 to April 30, 1998).11–13 Patients were
allowed to enter the study as many times as they
were hospitalised during the recruitment period,
resulting in 346 individuals with 404 admissions. For
the present analysis, in patients with more than
one admission during the recruitment period, the
first one was selected.
COPD diagnosis was established by the ward
pulmonologist and based on medical history, cur-
rent symptoms and available pulmonary function
tests, following the ERS guidelines.14 An exacerba-
tion was defined when the patient reported
an increase in dyspnea, in sputum production
or sputum purulence.15 Recruitment methods
and diagnosis criteria have been detailed in
previous papers.11–13 The Ethics Committees of
the participating hospitals approved the protocol,
and written informed consent was obtained from
all patients.
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During the recruitment hospital admission, patients
were asked to complete a questionnaire including a
wide range of variables that have been detailed
previously.11 Weight, height and tricipital skinfold
thickness were measured. At least 3 months after
admission, and during a clinically stable period of
COPD, patients performed a forced spirometric test
and provided arterial blood samples to measure gas
tensions. For the present analysis, we used informa-
tion on sociodemographic and clinical factors, as well
as on characteristics of received medical care—as
reported by the patient—in the year prior to the
recruitment admission. Patients were asked about the
physician (general practitioner (GP), pneumologist of
primary care, or pneumologist of hospital outpatient
clinics) who they feel was responsible of controlling
COPD. The question
’ ’
Who is, in your opinion, the
most important doctor in treatment and control of
your respiratory problems?’’ was developed ad hoc for
this study and piloted for understanding and feasi-
bility in 81 hospitalised COPD patients. Other ques-
tions included: number of visits to this physician,
number of hospital admissions due to COPD, current
pharmacological treatment (b2-agonists, anticholi-
nergics, methilxanthines, and inhaled and oral
corticosteroids) and non-pharmacological treatment
(influenza and pneumococcal vaccination, respiratory
rehabilitation and long-term oxygen therapy). A
detailed description of the contacts with the health
care system between the onset of symptoms and the
admission to the hospital (via ER) was also obtained,
and patients were classified into two pathways: non-
referred emergency-room visit—in the case of
patients who went straight to hospital when symp-
toms appeared—or referred emergency-room visit
—in the case of patients who had been visited by a
doctor first. Whenever possible, questions were
adapted from the Health Interview Survey in Barce-
lona.16 Detailed information about all the remaining
variables, sources of questions and methods for
spirometry and blood gas measures is available in
previous papers.11,12 A relapse was defined as a re-
admission for a COPD exacerbation within 30 days of
discharge. Information on re-admissions was obtained
from a national administrative database, as has been
described previously.12 Vital status was ascertained
through a record linkage with the Catalonia Mortality
Registry, as previously reported.12Statistical analysis
Comparison of patients’ sociodemographic, clinical
and medical care characteristics according to’ ’
type of physician who controls the disease’’ was
performed with ANOVA (for quantitative variables
of normal distribution), Kruskal–Wallis test (for
quantitative variables of non-normal distribution)
or w2 (for qualitative variables). Proportions and
95% confidence intervals of drug and non-drug
treatments were calculated from logistic regression
estimates, adjusting for FEV1, PO2 and previous
COPD admissions. Logistic regression models were
used to assess which factors are independently
associated with non-referred emergency-room vis-
its. Factors associated with length of stay were
assessed using Poisson regression model. Time from
discharge to relapse was used as the outcome
variable in a Cox proportional hazards multivariate
model to obtain variables independently associated
with the relapse. The analysis was performed with
Stata, release 8.0 (StataCorp, 2003, College Sta-
tion, TX, USA).Results
Most patients reported being controlled by a
pneumologist, in the primary care setting (11%) or
in the outpatient clinics (45%). One out of five
patients did not identify any doctor responsible of
their respiratory disease. Sociodemographic, clin-
ical and medical care characteristics of patients in
stability, according to type of physician who
controls the disease are shown in Table 1. Patients
controlled by the outpatients pneumologist were
younger, and exhibit lower PO2 and higher PCO2
values than the remaining. Patients treated by the
pneumologist, both in primary care and outpatient
setting, had suffered previous COPD admissions in
more proportion than the remaining, and presented
lower FEV1/FVC values, without differences in
FEV1. Among patients who did not identify a
responsible doctor there was a lower proportion
of married, a higher proportion of current smokers,
and COPD was milder than in the remaining
subjects—according to values of FEV1, FEV1/FVC,
PO2, and PCO2—although 65% of them had suffered
at least one previous COPD admission. Patients
controlled by the GP had a higher number of annual
control visits than those controlled by pneumolo-
gist, while the latter had better performance of the
inhaler manoeuvre. There were no differences in
knowledge about the disease or in satisfaction with
doctor.
Regarding the prescription of treatments for
COPD, Table 2 shows that, after adjusting for
severity (FEV1, PO2, and previous COPD admis-
sions), patients controlled by the pulmonologist
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J. Garcia-Aymerich et al.336(whatever the setting) had a higher prevalence of
drug and non-drug prescriptions, the difference
being especially higher for inhaled corticosteroids,
influenza vaccination and long-term oxygen ther-
apy. The proportion of subjects without any
respiratory drug treatment was higher in those
controlled by the GP and those not controlled by
any doctor.
Following the onset of symptoms, 30% of
patients were first visited by some doctor (whether
in primary care, hospital outpatient clinics, as a
home emergency, or others) and afterwards
referred to the ER, whereas the remaining 70%
attended directly the ER (non-referred ER visit)
(Table 3). The group being more likely to
have consulted a doctor prior to attending the ER
were those controlled by the GP. In a multi-
variate model, the only factors independently
associated with non-referred ER visit were: a
higher number of COPD admissions in the previous
year (HR 1.36, 1.14–1.62), and being controlled
by a pneumologist (HR 2.81, 1.50–5.25) or by
no doctor (HR 2.01, 0.97–4.13) in comparison
with GP.
Median time between the onset of symptoms
(when the exacerbation appeared) and arrival to
hospital was 6 days, statistically higher in
those controlled by the GP (Table 3), and in those
who were first visited by a doctor (7 days vs. 5 days,
P ¼ 0:02). Median hospital stay was 9 days.
While there was not a difference in hospital stay
according to the physician who controls the
disease, those patients who were first visited by
some doctor had a longer hospital stay (median 11
days vs. 8 days, P ¼ 0:05), as well as those with a
longer period (X6 days) between the onset of
symptoms and the admission (median 10 days vs. 8
days, P ¼ 0:01).
Six patients (2%) died during the recruitment
admission and, during the 30 days following
discharge, 34 (10%) died without having had a
subsequent admission. Among the remaining
(n ¼ 306), 66 (19%) presented a relapse (re-admis-
sion within 30 days). The type of doctor who
controls COPD, a shorter length of stay, or other
medical care related factors, were not associated
with relapse in the Cox multivariate model. The
Cox model including as the outcome both relapses
and deaths in the 30 days following discharge
yielded the same results.Ta
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COPD is a leading cause of morbidity and mortality
with a high economical cost due to frequent
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Health care in COPD Patients 337hospital admissions and intensive follow-up at
tertiary hospitals.5 An appropriate control of the
disease is needed to reduce its associated burden.
Our results, from a large cohort of moderate-to-
severe COPD patients recruited systematically in
four large university hospitals, showed that the
type of physician controlling the COPD patients is
related to substantial heterogeneity in the pre-
scription of treatments and in the ways of access to
hospital, even after adjusting for severity.
The first relevant finding of the present study was
that 21% of moderate-to-severe COPD patients
admitted to a hospital by an exacerbation reported
not being controlled regularly by any physician.
Although all the subjects in Spain have universal
access to health services, including an assigned GP,
a proportion of patients failed to identify a
physician whom they may feel is responsible of
controlling their respiratory disease. Since some of
these subjects were taking drugs or using oxygen
therapy, it is obvious that they had had at a given
period some control by a doctor over COPD. But
considering that only 7% of these subjects reported
any visit to a doctor for respiratory symptoms in the
year prior to recruitment as compared to the 100%
of all other groups, they likely experience a lack of
control of their disease. The higher prevalence of
current smokers and the lower prevalence of
married among this group of subjects, may suggest
a self-selected undercontrol of the disease. How-
ever, it is important to stand out that these
patients were less likely to receive influenza
vaccination, performed inhaled manoeuvres less
well, had lower access to respiratory rehabilita-
tion, and received less pharmacological treatment.
Previous studies have reported a high prevalence of
under treatment in COPD.17–19 Since most of the
later were performed in the general population it is
reasonable to believe that most of the under-
treatment is related to mild COPD. Our study shows
that undertreatment is as well common among
moderate and severe patients who require hospital
admissions, providing additional evidence for con-
cern about the current patterns of health care in
COPD.20
A second relevant finding is that a substantial
proportion of these moderate-to-severe patients
reported not being controlled by a pneumologist. Is
the fact of not being controlled by a pneumologist a
relevant issue? Since no evidence is available from
clinical trials, observational studies may provide
some useful information. In our study, patients
controlled by the GP were not milder than those
controlled by the pneumologist, contrarily to what
could have been expected according to ATS
recommendations.8 One could argue that, apart
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admissions, play a role in having contact with
specialists. However, 25% of those controlled by GP
reported two or more hospital admissions due to a
COPD exacerbation in the previous year. Other
countries have reported that differences in socio-
economic status and in health insurance schemes
are responsible of differences in utilisation of GP or
outpatient specialists.21 Irrespectively of the rea-
sons leading subjects to be controlled by one or
another physician, our data show that, even after
taking into account COPD severity, patients con-
trolled by the GP had a lower prevalence of drug
and non-drug treatments. Thus, it is probably
needed that COPD guidelines include whether COPD
patients should be cared by GP or by a specialist, as
well as the development and compliance with COPD
guidelines specific for GPs, with the final aim of a
better control of COPD in the population.
Thirdly, we were interested in assessing the
influence of the doctor who controls the disease
in the hospital admission route when a COPD
exacerbation occurs. In our area, and probably in
most European countries, due to the increasing
saturation of hospital beds and its associated high
cost, health authorities use to make a strong
emphasis on the need of consulting the GP before
going to an ER.1,2 Our data show that more than
two-thirds of COPD patients admitted in a tertiary
hospital for an exacerbation had acceded to the ER
from where they were admitted without a previous
medical visit. We were able to assess which factors
were associated to a direct access to hospital and
found that only being controlled by a GP prevented
such way of access. The fact that sociodemographic
factors had no influence on the admission pathway
suggests a good public health care system. The
question is whether, at the time of a COPD
exacerbation, a medical visit by the GP prior to
access to the hospital ER reduces the probability of
a subsequent admission. Wilkinson et al.22 found
that early therapy—in COPD subjects who con-
sulted a physician when the exacerbation appear-
ed—reduced recovery time and risk of further
hospitalisation, in a panel of 128 moderate COPD
patients. By contrast, we found that having been
visited by a doctor during the course of the
exacerbation, increased the time between onset
of symptoms and admission to hospital, and was
also associated with an increased length of stay,
which may suggest that different severity of
exacerbation requires from different health care
pathways. Both studies are coincident in the
importance of early intervention during a COPD
exacerbation. It seems reasonable to propose that
an early consultation to the GP should be advised.To which extent in more severe patients an early
hospital admission would be a better alternative
requires further investigation. Unfortunately,
health care alternatives such as early discharge
programs, home hospitalisation, self-management
plans or case-manager support were hardly avail-
able during the recruitment period in our area, thus
not being possible to investigate their possible
effect.
Several limitations of our study deserve further
consideration. One is the cross-sectional design of
our analysis. Information about health care before
the hospital admission was obtained by question-
naire and information bias cannot be excluded.
However, we restricted our questions to the period
of time ranging from the onset of the exacerbation
to the hospital admission, which should make a bias
less likely. By contrast, self-reported information
about the type of physician who controls the
disease could involve misclassification. We are not
aware about any study that had investigated the
validity of self-reported information about the
responsible physician in chronic conditions, a
concept from which content validity may involve
some difficulties. Other limitations like the pre-
sence of indication bias or the representativeness
of our sample have been largely discussed in
previous publications of the EFRAM study.11–13
WHO has recently proposed that coordinate and
comprehensive systems of health care should be
adopted for complex health problems, such as
chronic diseases.23 Our study has shown that lack of
control and variability in the patterns of care
among patients controlled by different types of
physician are common in moderate-to-severe COPD
patients admitted for a COPD exacerbation, despite
the lack of differences in COPD severity. These
results provide an additional support to the
necessity of fostering integral attention and con-
tinuity of care, as has been claimed for many other
chronic conditions.24Acknowledgements
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